Press release
Chronic Idiopathic Constipation Treatment Market is Predicted to Procure USD 19.7 Bn by 2033, Grow at a CAGR of 7.5% | Fact.MR
Chronic Idiopathic Constipation Treatment Market
Chronic idiopathic constipation (CIC) is a type of constipation that lasts a long period and has no clear explanation. It is a widespread condition that affects a large proportion of the global population, with a higher frequency among the elderly.
The chronic idiopathic constipation treatment market is predicted to expand significantly in the future years. The market is being driven by the rising prevalence of CIC, more awareness of the ailment, and growing need for effective treatment alternatives.
Get Free Sample Report to Grow Your Profit Margin:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8517
Furthermore, the aging population, sedentary lifestyles, and dietary changes are all contributing to the growing burden of CIC, driving up demand for therapeutic solutions.
Fiber supplements, laxatives, stool softeners, and prokinetic drugs are popular pharmaceuticals used to control CIC. Furthermore, advances in digital health technology are influencing the future of chronic idiopathic constipation treatment. Mobile software, wearable gadgets, and remote monitoring technologies are being developed to assist patients in tracking their bowel movements, nutrition, and exercise routines, as well as providing individualized management recommendations for CIC.
Key Takeaways from Market Study
Global sales of chronic idiopathic constipation medications are estimated to reach $19.7 billion by 2033.
The US market is rapidly developing due to the presence of important industry players.
The increasing frequency of chronic idiopathic constipation among Japan's elderly population is driving up demand for chronic idiopathic constipation treatment treatments.
Germany is likely to be a lucrative market for chronic idiopathic constipation medicine makers due to its excellent healthcare infrastructure.
"Key market participants are working to create cutting-edge solutions that can deliver effective and safe treatment for chronic idiopathic constipation sufferers," says a Fact.MR analyst.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8517
Competitive Landscape
According to Fact.MR, a market research and competitive intelligence firm, key players in the chronic idiopathic constipation treatment market are focusing on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering with and acquiring other companies.
Leading businesses in the chronic idiopathic constipation treatment industry are currently seeking FDA clearance for newly developed drugs. Over the forecast period, obtaining FDA approval is expected to be one of the important focus areas for manufacturers of chronic idiopathic constipation drugs.
The FDA has just given the all-clear to several medications.
In February 2020, the FDA approved an osmotic laxative developed by Braintree Laboratories (Sebela) to treat adults with persistent idiopathic constipation.
In April 2020, Ironwood Pharmaceuticals, Inc. announced that the USPTO has issued certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS.
In March 2020, the US Food and Drug Administration granted Sebela Pharmaceuticals, Inc. approval to market Pizensy (lactitol).
Recent Market Developments
In Japan, EA Pharma and Mochida Pharmaceutical introduced the successful chronic constipation drug 'Movicol HD' in May 2022.
In April 2022, the United States Food and Drug Administration (USFDA) authorized Ibsrela, a drug made by Ardelyx, Inc. This NHE3 inhibitor is prescribed to adult patients with IBS-C (irritable bowel syndrome with constipation).
Chronic Idiopathic Constipation Treatment Industry Research Segmentation
By Type:
Normal-transit Constipation
Slow-transit Constipation
By Therapy:
Pharmacological Therapies
Non-pharmacological Therapies
By Treatment:
Medication
Surgery
By Drug:
Serotonin-4 (5-Ht4) Receptor Agonist
Guanylate Cyclase-C Agonist
Laxatives
Stimulants
By Route of Administration:
Oral
Injectable
By End User:
Hospitals
Homecare
Specialty Clinics
By Region:
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA
๐๐๐๐ ๐๐จ๐ซ๐: https://www.factmr.com/report/chronic-idiopathic-constipation-treatment-market
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global chronic idiopathic constipation treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).
The study divulges essential insights on the market based on type (normal-transit constipation, slow-transit constipation), therapy (pharmacological therapies, non-pharmacological therapies), treatment (medication, surgery), drug (serotonin-4 (5-Ht4) receptor agonist, guanylate cyclase-C agonist, laxatives, stimulants), route of administration (oral, injectable), and end user (hospitals, homecare, specialty clinics), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
๐๐จ๐ง๐ญ๐๐๐ญ:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
๐๐๐จ๐ฎ๐ญ ๐ ๐๐๐ญ.๐๐
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Idiopathic Constipation Treatment Market is Predicted to Procure USD 19.7 Bn by 2033, Grow at a CAGR of 7.5% | Fact.MR here
News-ID: 3504763 • Views: โฆ
More Releases from Fact.MR
USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Develo โฆ
The U.S. microbiome skincare market is projected to experience rapid, data-driven growth over the next decade, driven by rising consumer awareness, ingredient innovation, and the integration of personalized diagnostics. Analysts estimate the U.S. microbiome skincare segment at approximately USD 0.13 billion in 2025, with a projected increase to USD 0.35 billion by 2035, representing a compound annual growth rate (CAGR) of 10.4%.
To access the complete data tables and in-depth insights,โฆ
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future โฆ
The U.S. lubricants market is projected to experience steady growth through 2035, driven by shifts in mobility, industrial demand, and sustainability trends. The market was valued at approximately $41.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $52 billion by 2035.
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12463
โฆ
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: K โฆ
"Demand for intermodal freight transport connecting the UK and continental Europe is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising trade volumes, decarbonization mandates, and digital logistics innovations. The intermodal market, encompassing rail, short-sea shipping, and last-mile road delivery, is expected to handle over 18 million TEUs (twenty-foot equivalent units) annually by 2035, up from 10.2 million TEUs in 2025.
To access the completeโฆ
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Fut โฆ
The United States hydroxyapatite (HAp) market is projected to experience sustained, data-driven growth from 2025 through 2035, fueled by rising clinical demand, technological innovation, and expanded applications in regenerative medicine. Market modeling indicates that U.S. consumption of hydroxyapatite will nearly double over the next decade, with strong adoption in orthopedic, dental, and advanced biomaterial sectors.
To access the complete data tables and in-depth insights, request a Discount On The Report here:โฆ
More Releases for Constipation
Major Growth Driver Identified in 2025 Constipation Laxative Market: Increasing โฆ
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Constipation Laxative Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for constipation laxatives has experienced robust growth in the past few years. An upturn from $7 billion in 2024 to $7.37 billion in 2025, achieving a compound annual growth rate (CAGR) ofโฆ
Evolving Market Trends In The Opioid-Induced Constipation Treatment Industry: St โฆ
The Opioid-Induced Constipation Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Opioid-Induced Constipation Treatment Market Size During the Forecast Period?
The opioid-induced constipation treatment market, valued at $1.78 billion in 2024, is projected to increase to $1.9 billion in 2025, growingโฆ
Key Trends Shaping the Future Constipation Laxative Market From 2025-2034: Innov โฆ
How Are the key drivers contributing to the expansion of the constipation laxative market?
The rising prevalence of constipation is expected to boost the growth of the constipation laxative market. Constipation, characterized by infrequent or difficult bowel movements, is becoming more common due to changes in diet, sedentary lifestyles, inadequate fluid intake, and medical conditions. Constipation laxatives help relieve this condition by stimulating bowel movements or softening stools. A 2024 surveyโฆ
Leading Element Driving Change in the Constipation Laxative Market in 2025: Incr โฆ
What Is the Estimated Market Size and Growth Rate for the Constipation Laxative Market?
The market for constipation laxatives has seen substantial expansion in the past few years. It is projected to further expand from $7 billion in 2024 to $7.44 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this growth during the historical period include an increase in the elderly population, sedentary lifestyles,โฆ
[Latest] Constipation Treatment Market : An Overview
The ""Constipation Treatment Market"" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Constipation Treatment Market, 2024-2031
Verified Market Research's most recent report, ""Constipation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030,"" provides an in-depthโฆ
How to Improve Constipation - Cassia Fistula Extract
Cassia Fistula Extract is a natural plant ingredient extracted from the friut of the Cassia Fistula tree and is widely used in traditional Chinese medicine and modern medicine.
Here are some common applications of Cassia Fistula Extract [https://www.ie-extract.com/cassia-fistula-extract-cassia-fistula-extract-treatment-of-constipation-product/]:
Promotes bowel movement and relieves constipation: Cassia Fistula Extract is believed to promote bowel movement and relieve constipation. Research shows that its active ingredients can stimulate intestinal motility, increase bowel movement frequency, and improveโฆ
